Meeting
2012 ASCO Annual Meeting
Correlation of survival with tumor antigen expression in patients with newly diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell vaccine.
Authors
Surasak Phuphanich
Neuro-Oncology Program, Cedars-Sinai Medical Center, Los Angeles, CA
Surasak Phuphanich , Christopher Jay Wheeler , Jeremy Rudnick , Mia Mazer , Hong Qiang Wang , Miriam Nuno , Jaime Richardson , Xuemo Fan , Jianfei Ji , Ray M Chu , James Bender , Elma S. Hawkins , Chirag Patil , Keith L. Black , John Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00576641
Citation
J Clin Oncol 30, 2012 (suppl; abstr 2087)
DOI
10.1200/jco.2012.30.15_suppl.2087
Abstract #
2087
Poster Bd #
18B
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).
First Author: Daniela Annenelie Bota
Poster
2011 ASCO Annual Meeting
Glioma-associated antigens associated with prolonged survival in a phase I study of ICT-107 for patients with newly diagnosed glioblastoma.
First Author: S. Phuphanich
Poster
2014 ASCO Annual Meeting
Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).
First Author: Gordana Vlahovic
Poster
2012 ASCO Annual Meeting
A randomized, double‑blind, controlled phase IIb study of the safety and efficacy of ICT‑107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation.
First Author: Elma S. Hawkins